FXYD5

FXYD domain containing ion transport regulator 5

Identifiers

FXYD5; DYSAD; IWU1; KCT1; OIT2; PRO6241; RIC

External IDs

OMIM: 606669 MGI: 1201785 HomoloGene: 7458 GeneCards: FXYD5 Gene

Gene Ontology
Molecular function	• actin binding • ion channel activity • cadherin binding
Cellular component	• membrane • integral to membrane
Biological process	• ion transport • microvillus assembly • negative regulation of calcium-dependent cell-cell adhesion
Sources: Amigo / QuickGO

RNA expression pattern

More reference expression data

Orthologs

Species

Human

Mouse

RefSeq (mRNA)

RefSeq (protein)

Location (UCSC)

Chr 19:
35.65 – 35.66 Mb

Chr 7:
31.82 – 31.83 Mb

PubMed search

[1]

[2]

FXYD domain-containing ion transport regulator 5 is a protein that in humans is encoded by the FXYD5 gene.^[1]

This reference sequence was derived from AF161462.1 and ESTs; validated by multiple replicate ESTs and human genomic sequence. This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, has not been characterized as a protein. Two transcript variants have been found for this gene, and they are both predicted to encode the same protein. [RefSeq curation by Kathleen J. Sweadner, Ph.D., sweadner@helix.mgh.harvard.edu.]^[1]

References

^ ^a ^b "Entrez Gene: FXYD5 FXYD domain containing ion transport regulator 5". http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=53827.

Nam JS, Hirohashi S, Wakefield LM (2007). "Dysadherin: a new player in cancer progression". Cancer Lett. 255 (2): 161–9. doi:10.1016/j.canlet.2007.02.018. PMC 2094007. PMID 17442482. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2094007.
Adams MD, Kerlavage AR, Fleischmann RD et al. (1995). "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence" (PDF). Nature 377 (6547 Suppl): 3–174. PMID 7566098. http://www.columbia.edu/itc/biology/pollack/w4065/client_edit/readings/nature377_3.pdf.
Sweadner KJ, Rael E (2001). "The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression". Genomics 68 (1): 41–56. doi:10.1006/geno.2000.6274. PMID 10950925.
Zhang QH, Ye M, Wu XY et al. (2001). "Cloning and Functional Analysis of cDNAs with Open Reading Frames for 300 Previously Undefined Genes Expressed in CD34+ Hematopoietic Stem/Progenitor Cells". Genome Res. 10 (10): 1546–60. doi:10.1101/gr.140200. PMC 310934. PMID 11042152. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=310934.
Omasa T, Chen YG, Mantalaris A, Wu JH (2001). "A cDNA from human bone marrow encoding a protein exhibiting homology to the ATP1gamma1/PLM/MAT8 family of transmembrane proteins". Biochim. Biophys. Acta 1517 (2): 307–10. PMID 11342114.
Ino Y, Gotoh M, Sakamoto M et al. (2002). "Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis". Proc. Natl. Acad. Sci. U.S.A. 99 (1): 365–70. doi:10.1073/pnas.012425299. PMC 117566. PMID 11756660. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=117566.
Strausberg RL, Feingold EA, Grouse LH et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=139241.
Sato H, Ino Y, Miura A et al. (2003). "Dysadherin: expression and clinical significance in thyroid carcinoma". J. Clin. Endocrinol. Metab. 88 (9): 4407–12. doi:10.1210/jc.2002-021757. PMID 12970317.
Clark HF, Gurney AL, Abaya E et al. (2003). "The Secreted Protein Discovery Initiative (SPDI), a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A Bioinformatics Assessment". Genome Res. 13 (10): 2265–70. doi:10.1101/gr.1293003. PMC 403697. PMID 12975309. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=403697.
Shimada Y, Yamasaki S, Hashimoto Y et al. (2004). "Clinical significance of dysadherin expression in gastric cancer patients". Clin. Cancer Res. 10 (8): 2818–23. doi:10.1158/1078-0432.CCR-0633-03. PMID 15102690.
Shimada Y, Hashimoto Y, Kan T et al. (2004). "Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma". Oncology 67 (1): 73–80. doi:10.1159/000080289. PMID 15459499.
Shimamura T, Yasuda J, Ino Y et al. (2004). "Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells". Cancer Res. 64 (19): 6989–95. doi:10.1158/0008-5472.CAN-04-1166. PMID 15466191.
Gerhard DS, Wagner L, Feingold EA et al. (2004). "The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=528928.
Wu D, Qiao Y, Kristensen GB et al. (2005). "Prognostic significance of dysadherin expression in cervical squamous cell carcinoma". Pathol. Oncol. Res. 10 (4): 212–8. doi:10.1007/BF03033763. PMID 15619642.
Nishizawa A, Nakanishi Y, Yoshimura K et al. (2005). "Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients". Cancer 103 (8): 1693–700. doi:10.1002/cncr.20984. PMID 15751018.
Batistatou A, Scopa CD, Ravazoula P et al. (2006). "Involvement of dysadherin and E-cadherin in the development of testicular tumours". Br. J. Cancer 93 (12): 1382–7. doi:10.1038/sj.bjc.6602880. PMC 2361540. PMID 16333245. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2361540.
Batistatou A, Makrydimas G, Zagorianakou N et al. (2007). "Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies". Placenta 28 (5–6): 590–2. doi:10.1016/j.placenta.2006.09.004. PMID 17084448.
Batistatou A, Peschos D, Tsanou H et al. (2007). "In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin". Br. J. Cancer 96 (9): 1404–8. doi:10.1038/sj.bjc.6603743. PMC 2360179. PMID 17437014. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2360179.

FXYD5

References

Further reading